SEC Form PRE 14A filed by Agilent Technologies Inc.
$A
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $157.00 | Overweight | Wells Fargo |
| 7/10/2024 | $135.00 → $150.00 | Neutral → Buy | Citigroup |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/3/2024 | $135.00 | Hold | Jefferies |
| 4/5/2024 | $145.00 → $163.00 | Hold → Buy | Stifel |
| 12/13/2023 | $140.00 | Outperform | Wolfe Research |
| 12/12/2023 | $130.00 → $133.00 | Buy → Neutral | BofA Securities |
| 11/17/2023 | $163.00 → $125.00 | Buy → Neutral | UBS |
Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00
Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously
Wolfe Research downgraded Agilent from Outperform to Peer Perform
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full
Delivers solid results in Q4; initiates FY25 guidance Fourth-quarter fiscal year 2024 Revenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023. GAAP net income of $351 million; earnings per share (EPS) of $1.22, down 25% from the fourth quarter of 2023. Non-GAAP(2) net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023. Full fiscal year 2024 Revenue of $6.51 billion, down 4.7% on a reported basis and down 4.7% core(1) year-over-year. GAAP net income of $1.289 billion; EPS of $4.43, up 6% year-over-year. Non-GAAP(2) net income of $1.539 billion; EPS of $5.29, down 3% year-over-year. Fiscal year 2025 an
Agilent Technologies, Inc. (NYSE:A) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includ
PRE 14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
10-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full
Building the lab of the future today by enhancing lab productivity with robust and reliable automation technology Agilent Technologies Inc. (NYSE:A) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes. Automation is becoming increasingly critical for labs as they navigate the competitive landscape.
LEWISVILLE, Ark., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium") (TSXV:SLI) (NYSE:A), a leading near-commercial lithium developer, and Equinor, a global energy leader, today announced that its jointly-owned U.S. subsidiary, SWA Lithium LLC, has closed the US$225 million grant from the U.S. Department of Energy's ("DOE") Office of Manufacturing & Energy Supply Chains. The grant will support construction of Phase 1 of the South West Arkansas ("SWA") project. "Closing of the DOE grant is a testament to the caliber of the South West Arkansas project," said David Park, CEO and Director of Standard Lithium. "SWA is one of the highest-grade lithium brine project
Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals while reducing energy consumption up to 30%. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9270251-agilent-unveils-8
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)